||||||||||KQ-2002 / Novatim Immune Therap Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma (clinicaltrials.gov) - Dec 28, 2023 P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital Trial completion date: Dec 2023 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2024
||||||||||KQ-2003 / Shanghai Keqi Pharma Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 28, 2023 P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital Trial completion date: Dec 2023 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2024 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jan 2022 --> Sep 2024